10.25673/120599">
Proceedings of International Conference on Applied Innovation in IT  ·  2025/06/27  ·  Vol. 13  ·  Issue 2  ·  pp. 729–736
Molecular Study of Multidrug-Resistant Integrons Associated with Acinetobacter baumannii Isolated from Clinical Samples
Ali Adel Abud Alhussein and Suaad Abid Fazaa
📄 Download PDF DOI: <a href="http://dx.doi.org/10.25673/120599">10.25673/120599</a>
Abstract
The study investigated the prevalence of class one, two, and three integrons in A. baumannii isolates obtained from patients admitted to government hospitals in Diwaniyah (General Diwaniyah, Women and Children, al Hussein, and Burns Hospital) in Al-Qadisiyah Governorate, Iraq. From September 2024 to January 2025, 150 non-duplicate samples were collected, including 21 (14%) wound swabs, 36 (24%) burn swabs, 32 (21.33%) blood samples, 34 (22.66%) urine samples, and 27 (18%) tracheal swabs. After initial identification on MacConkey agar, blood agar, and chromium agar, the samples were chemically tested and Gram-stained. The VITEK2 compact system was used to confirm the diagnosis. This study showed that 117 (78%) of the samples showed bacterial growth, of which 40 (34.18%) were confirmed as A. baumannii, distributed as follows: 3 isolates (14.28%) from wounds, 6 isolates (16.66%) from burn swabs, 13 isolates (40.62%) from blood, 6 isolates (17.64%) from urine samples, and 12 isolates (44.44%) from tracheal swabs. The data indicated that tracheal swabs had the highest percentage of A. baumannii isolation, followed by blood, urine, burns, and wounds (44.44%, 40.62%, 17.64%, 16.66%, and 14.28%, respectively). Antibiotic susceptibility testing was performed using the Vitek device for 20 antibiotics. The purity and concentration of genomic DNA were measured using a Nanodrop instrument, and a conventional PCR reaction was set up to detect integrons using specific primers provided by Promega. The products were analyzed by agarose gel electrophoresis. The highest prevalence was found for class I integrons (23 samples, 57.5%), followed by class III (9 samples, 22.5%), and class II (6 samples, 15%) out of the 40 A. baumannii-positive samples.
Keywords
Acinetobacter baumannii Antibiotic Resistance Multidrug Resistance Integrons Clinical Isolates.
References
  1. H. Ejaz, M. Ahmad, S. Younas, K. Junaid, K. O. A. Abosalif, A. E. Abdalla, A. A. M. Alameen, M. Y. M. Elamir, S. N. A. Bukhari, N. Ahmad, et al., "Molecular epidemiology of extensively-drug resistant Acinetobacter baumannii sequence type 2 co-harboring bla(NDM) and bla(OXA) from clinical origin," Infect. Drug Resist., vol. 14, pp. 1931–1939, 2024.
  2. A. Chukamnerd, K. Singkhamanan, V. Chongsuvivatwong, P. Palittapongarnpim, Y. Doi, R. Pomwised, and K. Surachat, "Whole-genome analysis of carbapenem-resistant Acinetobacter baumannii from clinical isolates in Southern Thailand," Computational and Structural Biotechnology Journal, vol. 20, pp. 545–558, 2022.
  3. A. Pompilio, D. Scribano, M. Sarshar, G. Di Bonaventura, A. T. Palamara, and C. Ambrosi, "Gram-negative bacteria holding together in a biofilm: the Acinetobacter baumannii way," Microorganisms, vol. 9, p. 1353, 2021.
  4. L. R. Marks, R. M. Reddinger, and A. P. Hakansson, "Biofilm formation enhances fomite survival of Streptococcus pneumoniae and Streptococcus pyogenes," Infect. Immun., vol. 82, pp. 1141–1146, 2014.
  5. M. A. Horcajada, M. Monsalve, M. A. Reuter, J. R. Figueiredo, A. L. Dupont, D. Bladé, and J. Vila, "Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii clinical isolates in Barcelona, Spain," Antimicrob. Agents Chemother., vol. 56, no. 5, pp. 2766–2771, 2012.
  6. K. M. Lee, D. Y. Lee, and J. H. Jung, "Genomic analysis of Acinetobacter baumannii clinical isolates in South Korea: Resistance mechanisms and clonal diversity," Front. Microbiol., vol. 13, p. 834567, 2022.
  7. S. T. Peleg, H. Seifert, and D. L. Paterson, "Acinetobacter baumannii: Emergence of a successful pathogen," Clin. Microbiol. Rev., vol. 21, no. 3, pp. 538–582, 2008.
  8. M. T. Mohammed, A. K. Ali, and H. S. Al-Shuwaikh, "Detection of blaOXA-23-like and blaNDM-1 genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq," New Microbes New Infect., vol. 43, p. 100915, 2021.
  9. A. R. Abdi, F. Karami, M. Azizi, and S. R. Shakibaie, "Phenotypic and genotypic characterization of biofilm formation in clinical isolates of Acinetobacter baumannii," Iran. J. Basic Med. Sci., vol. 21, no. 3, pp. 287–292, 2018.
  10. B. Harding, D. Henningsen, and T. Begun, "Carbapenem-resistant Acinetobacter baumannii: Epidemiology, clinical impact, and infection control," Curr. Opin. Infect. Dis., vol. 31, no. 4, pp. 364–372, 2018.
  11. C. F. Higgins, S. Overdevest, M. J. Riley, J. C. Boyce, and T. T. Nguyen, "Molecular mechanisms of resistance to colistin in Acinetobacter baumannii," J. Antimicrob. Chemother., vol. 73, no. 6, pp. 1539–1545, 2018.
  12. M. A. Durante-Mangoni, L. Andini, and G. Zarrilli, "Extensively drug-resistant Acinetobacter baumannii: Clinical impact and therapeutic options," Pathog. Dis., vol. 75, no. 5, pp. 1–8, 2017.
  13. T. Krizova, M. Dijkshoorn, L. Nemec, "Diversity and evolution of AbaR genomic resistance islands in Acinetobacter baumannii strains of European clone I," Antimicrob. Agents Chemother., vol. 55, no. 7, pp. 3201–3206, 2011.
  14. M. Kempf and H. Rolain, "Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options," Int. J. Antimicrob. Agents, vol. 39, no. 2, pp. 105–114, 2012.
  15. Y. Hu, Y. He, X. Zhang, Z. Wu, and G. Zhao, "Comparative genomic analysis reveals the evolution and genetic diversity of multidrug-resistant Acinetobacter baumannii," BMC Genomics, vol. 21, p. 239, 2020.
  16. J. R. Evans, T. Y. Tran, M. L. Smith, and K. A. Wilson, "Biofilm-related infections in Acinetobacter baumannii: Pathogenesis and therapeutic strategies," Front. Cell. Infect. Microbiol., vol. 10, p. 558, 2020.
  17. M. Vijayakumar, V. K. Prasanna, A. Murugan, and R. K. Kannan, "Molecular characterization of Acinetobacter baumannii clinical isolates in India: Multidrug resistance and biofilm formation," Indian J. Med. Microbiol., vol. 39, no. 1, pp. 32–38, 2021.
  18. N. Nowak, T. S. Seifert, and A. Higgins, "Clinical and economic burden of Acinetobacter baumannii infections in the ICU: A systematic review," Crit. Care Med., vol. 48, no. 12, pp. 1743–1751, 2020.
  19. G. Perez, R. J. Hujer, A. Marshall, D. M. Hujer, J. M. Domitrovic, and R. A. Bonomo, "Global challenge of multidrug-resistant Acinetobacter baumannii," Antimicrob. Agents Chemother., vol. 61, no. 6, e02591-16, 2017.
  20. C. Antunes, L. Visca, and H. Towner, "Acinetobacter baumannii: Evolution of a global pathogen," Pathog. Dis., vol. 71, no. 3, pp. 292–301, 2014.
  21. M. B. Wareham and D. J. Bean, "In vitro activity of colistin against multidrug-resistant Acinetobacter baumannii clinical isolates," Int. J. Antimicrob. Agents, vol. 33, no. 1, pp. 93–96, 2009.

Proceedings of the International Conference on Applied Innovations in IT by Anhalt University of Applied Sciences is licensed under CC BY-SA 4.0  ·  This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License

ICAIIT 2026
International Conference on Applied Innovation in IT
Navigation
Publisher
ISSN2199-8876
Publisher Edition Hochschule Anhalt
Location Anhalt University of Applied Sciences
Email leiterin.hsb@hs-anhalt.de
Phone +49 (0) 3496 67 5611
Address Building 01, Room 425
Bernburger Str. 55
D-06366 Köthen, Germany
Open Access License
CC BY-SA 4.0

All works are licensed under the Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), unless otherwise noted.

Published by ICAIIT in cooperation with Anhalt University of Applied Sciences.

© 2026 ICAIIT — International Conference on Applied Innovations in IT. Anhalt University of Applied Sciences, Köthen, Germany.
Visitors: site traffic counter